CompletedNot Applicable

FCH PET/MRI Parathyroid Localization

Canada47 participantsStarted 2018-04-03

Plain-language summary

A prospective trial comparing the accuracy of \[F-18\]-FCH PET/MRI to US and 99mTc-MIBI SPECT/CT for pre-operative parathyroid localization in patients with primary hyperparathyroidism

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Biochemically proven primary hyperparathyroidism * Indication for parathyroidectomy as per institutional guidelines Exclusion Criteria: * Contraindication for MRI as per current institutional guidelines. * Contraindication for Gadolinium injection as per current institutional guidelines. * Renal failure * Inability to lie supine for at least 45 minutes. * Any participant who is pregnant or breastfeeding. * Participants receiving erythropoietin (i.e. for hemochromatosis; might lead to false negative results due to stimulation of bone marrow metabolism) * Familial HPT syndromes * Participant currently being treated with any cytotoxic chemotherapy

What they're measuring

Accuracy of [F-18]-FCH PET/MRI in localization of diseased parathyroid gland

Timeframe: 1 month postoperatively

Trial details

NCT IDNCT03324893

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-06-23

View on ClinicalTrials.gov More 18F-fluorocholine trials